PRESS RELEASE · Research Update
Release date
TFA Reports Early Observations in 15 Dogs as Canine Osteoarthritis Study Preparations Continue
Selected cases showed improvements in walking and mobility; standardized studies will provide further evaluation
- Early observations in 15 dogs and selected case records document changes in mobility to inform further research.
- Preparations are underway for third-party research evaluating pain, mobility, dosing, and tolerability.
TFA Therapeutics, Inc. (OTCQB: RAJAF) reported early exploratory observations in 15 dogs and outlined its canine osteoarthritis research plans for TFA-01. Care records and visual documentation of selected cases compiled by the company showed improvements in walking and mobility in some dogs during the observation period. These observations helped inform plans for further research.
The company provided individual case records describing a return to walking around day 7 and improved mobility with discharge around day 14. These time points describe individual cases and do not represent outcomes across all 15 dogs. There was no concurrent control group.
TFA has arranged third-party canine osteoarthritis research, with preliminary cell studies and trial preparations underway. The planned protocol calls for screening dogs against inclusion criteria, assessing pain and mobility, and monitoring safety and tolerability during treatment. The study will combine complete case records, visual documentation, and statistical analyses.
TFA will use results from the initial stage to plan comparative studies with existing treatments. Canine osteoarthritis is the company's initial indication, and subsequent development will be guided by efficacy and safety results from formal studies.
These early exploratory observations in 15 dogs do not establish efficacy or an advantage over existing drugs.
About TFA
TFA Therapeutics, Inc. (OTCQB: RAJAF) is developing TFA-01, an Antcin A-based drug candidate, with canine osteoarthritis as its initial target indication. The program includes source material and formulation development, as well as safety and efficacy evaluation.
Forward-looking statements: The development plans described in this release may change in response to study results, regulatory requirements, and funding arrangements. Actual progress and outcomes may differ from current expectations.